Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus.
The company was incorporated in 2016 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -1.02 Increased by +29.66% | -0.89 Decreased by -14.61% |
| May 2, 24 | -0.48 Increased by +54.72% | -1.05 Increased by +54.29% |
| Feb 22, 24 | -0.86 Decreased by -13.16% | -1.01 Increased by +14.85% |
| Nov 2, 23 | -1.22 Decreased by -193.85% | -1.21 Decreased by -0.83% |
| Aug 3, 23 | -1.45 Decreased by -150.00% | -1.20 Decreased by -20.83% |
| May 4, 23 | -1.06 Decreased by -127.53% | -0.87 Decreased by -21.84% |
| Feb 23, 23 | -0.76 Decreased by -119.39% | -0.39 Decreased by -94.87% |
| Nov 3, 22 | 1.30 Increased by +58.54% | -0.21 Increased by +719.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | -4.10 M Decreased by -101.10% | -163.41 M Decreased by -193.21% | Increased by +3.99 K% Increased by +8.35 K% |
| Jun 30, 23 | -12.72 M Increased by +70.20% | -194.78 M Decreased by -154.63% | Increased by +1.53 K% Increased by +754.38% |
| Mar 31, 23 | 46.71 M Decreased by -96.20% | -140.96 M Decreased by -127.18% | Decreased by -301.76% Decreased by -815.63% |
| Dec 31, 22 | 21.79 M Decreased by -97.31% | -101.60 M Decreased by -119.34% | Decreased by -466.30% Decreased by -818.88% |
| Sep 30, 22 | 371.43 M Increased by +261.62% | 175.31 M Increased by +58.76% | Increased by +47.20% Decreased by -56.10% |
| Jun 30, 22 | -42.69 M Decreased by -124.53% | -76.49 M Decreased by -223.75% | Increased by +179.20% Increased by +404.38% |
| Mar 31, 22 | 1.23 B Increased by +203.20 K% | 518.62 M Increased by +407.04% | Increased by +42.17% Increased by +100.15% |
| Dec 31, 21 | 809.76 M Increased by +268.92 K% | 525.25 M Increased by +597.17% | Increased by +64.87% Increased by +100.18% |